Delivery Order SPE2DB22D3501-SPE2DB25FVE90

Award Date 4/8/25
Potential Completion Date 4/9/25
Potential Value $21K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. The contract has a firm fixed price of $1,521.58 and an ultimate completion date of February 10, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as the primary vehicle for...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 0.5 MG/0.5 ML PEN 0.5ML medical products. The contract has a ceiling value of $25,311.46 and runs through December 17, 2024. It is a firm-fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $1,504.92 and is a firm fixed-price, delivery order type contract with a period of performance through November 14, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $10,727.19 and a completion date of May 13, 2025. It is a firm fixed-price delivery order contract, without a set-aside designation. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 0.25 MG/0.5 ML PEN 0.5ML. The contract has a firm fixed price, with a ceiling value of $1,286.39, and a period of performance through March 18, 2025. This order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 0.25 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $14,924.26 and runs through October 18, 2024. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and expiring in November 2026. The IDC covers a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 0.25 mg/0.5 ml pen 0.5 ml. The contract has a ceiling value of $14,094.53 and a period of performance through July 5, 2024. It is a firm fixed-price, delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of WEGOVY 0.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, with a ceiling value of $2,158.22 and a completion date of June 26, 2025. The contract is a firm fixed-price delivery order, without any set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 1 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $5,078.22 and runs through April 8, 2025. It is a firm fixed price contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 1 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $5,153.25 and a period of performance through May 2, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that AmerisourceBergen holds with DLA Troop Support Medical, which provides a global...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FVE90
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $20,859.02 and runs through April 9, 2025. The contract is a firm fixed price delivery order, with no set-aside designation. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 through November 2026, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 7/8/25, 2:30 PM